RxDoctor Payments Data

Shun Sunder, MD

Cardiology · Lancaster, CANPI 1376557132

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.7% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 18.8% — the pattern of someone who eats at a lot of different presentations.

$609in general payments, 2019–2025

Across 32 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$114
  • Lexicon Pharmaceuticals, Inc.$79
  • E.r. Squibb & Sons, L.L.C.$73
  • Novartis$45
  • Irhythm Technologies, Inc.$39
  • Merck$37
  • plus $222 from 10 others

What the payments were for

  • Food & beverage$58296%
  • Education$264%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$609 in reported general payments places this provider in the 60th percentile of 156 cardiology providers in California.

See all cardiology providers in California

Medicare billing

Part B allowed, 2024
$371,619
Medicare patients
412
Services billed
3,586

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan259$288,019
JardianceEmpagliflozin225$281,846
EliquisApixaban192$214,334
FarxigaDapagliflozin Propanediol73$75,750
BrilintaTicagrelor64$48,515
VerquvoVericiguat17$23,377
KerendiaFinerenone15$19,130
XareltoRivaroxaban11$13,618
Metoprolol Succinate419$7,057
Repatha SureclickEvolocumab13$7,047
Repatha SyringeEvolocumab12$6,289
Ezetimibe50$3,323
Rosuvastatin Calcium84$2,409
Atorvastatin Calcium251$2,275
FenofibrateFenofibrate,micronized60$1,859

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$45$288,019259 claims
Boehringer IngelheimJardiance$14$281,846225 claims
AstraZenecaFarxiga, Brilinta$33$124,265137 claims
MerckVerquvo$37$23,37717 claims
BayerKerendia$33$19,13015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 156 cardiology providers in California.

Other cardiology in Lancaster

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →